Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14692523rdf:typepubmed:Citationlld:pubmed
pubmed-article:14692523lifeskim:mentionsumls-concept:C0020792lld:lifeskim
pubmed-article:14692523lifeskim:mentionsumls-concept:C0023467lld:lifeskim
pubmed-article:14692523lifeskim:mentionsumls-concept:C0079611lld:lifeskim
pubmed-article:14692523lifeskim:mentionsumls-concept:C0205369lld:lifeskim
pubmed-article:14692523pubmed:issue10lld:pubmed
pubmed-article:14692523pubmed:dateCreated2003-12-24lld:pubmed
pubmed-article:14692523pubmed:abstractTextAssociation between certain surface markers and acute myelogenous leukemia (AML) with t(8;21) has been described. The specificity and the predictive values of these markers have never been assessed. In this study, we aimed, to explore whether a specific pattern could predict for this translocation. Of 405 consecutive AML, 18 (4.4%) had the t(8;21). Patients with this cytogenetic abnormality showed higher frequency of CD34 (P = 0.003), HLA-DR (P = 0.03), Tdt (P = 0.02), CD19 (P < 0.0001), and CD56 (P < 0.0001) and lower CD33 (P = 0.0001). Taken singly, the sensitivity of these markers for AML with t(8;21) ranged between 39 and 100% with CD34+ having the highest and CD33- having the lowest and the positive predictive values (PPV) ranged between 5 and 21% with CD19+ having the highest and HLA-DR+ having the lowest. When combinations of different markers were analyzed by multivariate analysis, the pattern CD34+/HLA-DR+/MPO+ was found to have the highest sensitivity (100%) with a PPV of 14% and the pattern CD34+/CD19+/CD56+ had the highest PPV (100%) with a sensitivity of 67%. We conclude that AML with t(8;21) is better identified by a combination of markers than by a single antigen pattern, the absence of CD34+, HLA-DR+ or MPO+ would preclude and the expression of the pattern CD34+/CD19+/CD56+ is highly predictive and could serve as a screening criteria for the t(8;21).lld:pubmed
pubmed-article:14692523pubmed:languageenglld:pubmed
pubmed-article:14692523pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14692523pubmed:citationSubsetIMlld:pubmed
pubmed-article:14692523pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14692523pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14692523pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14692523pubmed:statusMEDLINElld:pubmed
pubmed-article:14692523pubmed:monthOctlld:pubmed
pubmed-article:14692523pubmed:issn1042-8194lld:pubmed
pubmed-article:14692523pubmed:authorpubmed-author:SutherlandHea...lld:pubmed
pubmed-article:14692523pubmed:authorpubmed-author:HoggeDonna...lld:pubmed
pubmed-article:14692523pubmed:authorpubmed-author:DalalBakul...lld:pubmed
pubmed-article:14692523pubmed:authorpubmed-author:HorsmanDougla...lld:pubmed
pubmed-article:14692523pubmed:authorpubmed-author:BarnettMichae...lld:pubmed
pubmed-article:14692523pubmed:authorpubmed-author:NantelStephen...lld:pubmed
pubmed-article:14692523pubmed:authorpubmed-author:NevillThomas...lld:pubmed
pubmed-article:14692523pubmed:authorpubmed-author:ShepherdJohn...lld:pubmed
pubmed-article:14692523pubmed:authorpubmed-author:KhouryHaytham...lld:pubmed
pubmed-article:14692523pubmed:authorpubmed-author:TozeCindy LCLlld:pubmed
pubmed-article:14692523pubmed:authorpubmed-author:ConneallyEbhi...lld:pubmed
pubmed-article:14692523pubmed:issnTypePrintlld:pubmed
pubmed-article:14692523pubmed:volume44lld:pubmed
pubmed-article:14692523pubmed:ownerNLMlld:pubmed
pubmed-article:14692523pubmed:authorsCompleteYlld:pubmed
pubmed-article:14692523pubmed:pagination1713-8lld:pubmed
pubmed-article:14692523pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:14692523pubmed:meshHeadingpubmed-meshheading:14692523...lld:pubmed
pubmed-article:14692523pubmed:meshHeadingpubmed-meshheading:14692523...lld:pubmed
pubmed-article:14692523pubmed:meshHeadingpubmed-meshheading:14692523...lld:pubmed
pubmed-article:14692523pubmed:meshHeadingpubmed-meshheading:14692523...lld:pubmed
pubmed-article:14692523pubmed:meshHeadingpubmed-meshheading:14692523...lld:pubmed
pubmed-article:14692523pubmed:meshHeadingpubmed-meshheading:14692523...lld:pubmed
pubmed-article:14692523pubmed:meshHeadingpubmed-meshheading:14692523...lld:pubmed
pubmed-article:14692523pubmed:meshHeadingpubmed-meshheading:14692523...lld:pubmed
pubmed-article:14692523pubmed:meshHeadingpubmed-meshheading:14692523...lld:pubmed
pubmed-article:14692523pubmed:meshHeadingpubmed-meshheading:14692523...lld:pubmed
pubmed-article:14692523pubmed:meshHeadingpubmed-meshheading:14692523...lld:pubmed
pubmed-article:14692523pubmed:meshHeadingpubmed-meshheading:14692523...lld:pubmed
pubmed-article:14692523pubmed:meshHeadingpubmed-meshheading:14692523...lld:pubmed
pubmed-article:14692523pubmed:meshHeadingpubmed-meshheading:14692523...lld:pubmed
pubmed-article:14692523pubmed:meshHeadingpubmed-meshheading:14692523...lld:pubmed
pubmed-article:14692523pubmed:meshHeadingpubmed-meshheading:14692523...lld:pubmed
pubmed-article:14692523pubmed:meshHeadingpubmed-meshheading:14692523...lld:pubmed
pubmed-article:14692523pubmed:meshHeadingpubmed-meshheading:14692523...lld:pubmed
pubmed-article:14692523pubmed:meshHeadingpubmed-meshheading:14692523...lld:pubmed
pubmed-article:14692523pubmed:year2003lld:pubmed
pubmed-article:14692523pubmed:articleTitleAcute myelogenous leukemia with t(8;21)--identification of a specific immunophenotype.lld:pubmed
pubmed-article:14692523pubmed:affiliationLeukemia/BMT Program of British Columbia, Vancouver, Canada. khaytham@uhnres.utoronto.calld:pubmed
pubmed-article:14692523pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14692523pubmed:publicationTypeComparative Studylld:pubmed